Shareholder Information
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.
The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
Corporate Presentation
An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be download here.
MDxHealth Corporate Presentation 2021
Corporate Governance Charter
MDxHealth attaches great value to corporate governance practices. On September 7, 2011, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles and the provisions of the Belgian Corporate Governance Code 2009 issued on March 12, 2009 by the Corporate Governance Committee.
The full text of MDxHealth’s Corporate Governance Charter can be downloaded here.
MDxHealth is listed on the Euronext under the ticker symbol MDXH.
MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.
Code of Ethics
The full text of MDxHealth’s Code of Ethics can be downloaded here.
Dealing Code
As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here.
Share capital history
The history of the share capital issuance since the inception of the company can be found here:
Transparency Declarations of the largest shareholders
The table below provides an overview of the shareholders that filed a notification with MDxHealth SA pursuant to applicable transparency disclosure rules. Although the applicable transparency disclosure rules require that a disclosure must be made by each person passing or falling under one of the relevant thresholds, it is possible that the information below in relation to a shareholder is no longer up-to-date. The percentages of voting rights mentioned in the table have been calculated on the basis of the currently outstanding shares.
| SHAREHOLDER (OR PARTY REPRESENTING SHAREHOLDERS) | MVM PARTNERS LLP | BIOVEST NV | VALIANCE ASSET MANAGEMENT | SOLEUS CAPTIAL MANAGEMENT, L.P. | SCORPIAUX BVBA |
|---|---|---|---|---|---|
| % OF OUTSTANDING SHARES | 22.23% | 9.36% | 12.30% | 5.32% | 4.26% |
| SITUATION AS OF | May 15, 2020 | Jan. 26, 2021 | May 15, 2020 | Jan. 26, 2021 | May 15, 2020 |
| NOTIFICATION RECEIVED | May 18, 2020 | Feb. 1, 2021 | May 21, 2020 | Feb. 1, 2021 | June 2, 2020 |
| NOTIFICATION FORM | Click here to view form | Click here to view form | Click here to view form | Click here to view form | Click here to view form |
*Percentage calculated as per the date of the relevant transaction and taking into account the total number of outstanding shares as per such date
Each natural or legal person acquiring or transferring MDxHealth’s shares is required to notify MDxHealth and the Financial Services and Markets Authority (FSMA) each time their shareholding crosses a threshold of three percent (3%) of the total number of outstanding shares (the denominator). Such notification is also required each time, as a result of an acquisition or transfer a threshold of five percent (5%) and a multiple of five percent (5%) is crossed. Complete information regarding this requirement is found in Article 14 of MDxHealth’s articles of association.
The transparency notifications should be reported within 5 business days of crossing the threshold by following the procedures outlined on the FSMA website found here.
A copy of the transparency notification should also be emailed and faxed to the company, to the attention of: Ron Kalfus, Chief Financial Officer, at ir@mdxhealth.com and fax +32 4 259 78 75.
Special and Extraordinary Shareholders' Meeting (July 30, 2020)
Minutes of the Special General Meeting of the Shareholders July 30, 2020: English I Français
Minutes of the Extraordinary General Meeting of the Shareholders July 30, 2020: Français
Convening Notice: English I Français
Explanatory Note: English I Français
Proxy Form: English/Français
Voting by Mail Form: English/Français
Overview of Outstanding Voting Rights: Français I English
Special Board Report pursuant to Article 7:199 of the Belgian Companies and Associations Code: English I Français
Previous Shareholder Meetings
AGM Minutes – May 28 2020 – EN (free translation)
AGM Minutes – May 28 2020 – FR
EGM Minutes – May 28 2020 – FR
AGM 2019 – minutes (French) FINAL SIGNED.pdf
May 25, 2012, board report for extraordinary general shareholders’ meeting – English.pdf
May 25, 2012, board report for extraordinary general shareholders’ meeting – Francais.pdf
May 25, 2012, extraordinary general shareholder meeting non-proceedings minutes – Francais.pdf
May 25, 2012, annual general shareholders’ meeting minutes – Francais.pdf
Paying Agent
The financial service for the shares of the company is provided in Belgium by ING. Shareholders should inform themselves about the costs that other financial intermediaries may charge in connection with paying agency services.
Special Reports of the Board and Auditor
Board Report in relation to the capital increase of 26 January 2021 (FR)
Board Report in relation to the capital increase of 26 January 2021 (EN)
Auditor Report in relation to the capital increase of 26 January 2021 (FR)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (FR)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (FR)
2019-09-Auditors Report art 596
2019-09-EN-Board Report art 596
2019-09-FR-Board Report art 596
2018-03-Auditors Report art 596
2018-03-EN-Board Report art 596
2018-03-FR-Board Report art 596
006 Board Report 596 (FR)[5].pdf
604 Board Report (FR) exec.pdf
583 596 598 Board Report and Plan (EN).pdf
583 596 598 Board Report and Plan (FR).pdf
R Mdx art 596-598 Plan d’options sur Action May 2017 – 2.500.000 SOP.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf(FR).pdf
Rapport du commissaire, article 596, 31 octobre 2006 .pdf
Rapport du conseil d’administration. article 604 avril 2016.pdf
604 Board Report (FR) exec.pdf
Rapport du Commissaire, article 602, 18 septembre 2015.pdf
Rapport du Conseil d’Administration, article 602, 18 septembre 2015.pdf
Report of the Board, article 602, September 18, 2015.pdf
Rapport du commissaire – article 596, 23 juin 2015.pdf
Rapport du conseil d’administration, 23 juin 2015.pdf
Rapport du conseil d’administration, 4 novembre 2014.pdf
Rapport du conseil d’administration – articles 583-596-598 – 30 avril 2014.pdf
Rapport du commissaire – articles 596-598 – 30 avril 2014.pdf
Rapport du commissaire, articles 596 et 598, 24 juin 2013.pdf
Rapport du conseil d’administration, 24 juin 2013.pdf
Rapport du conseil d’administration, article 604, 30 avril 2013.pdf
Rapport du commissaire, articles 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 603 juncto 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 18 avril 2012.pdf
Rapport du commissaire, articles 596:598, 19 avril 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 27 mai 2011.pdf
Rapport du commissaire, article 596, 27 mai 2011.pdf
Rapport du commissaire, article 596, 4 avril 2011.pdf
Rapport du conseil d’administration, article 603 juncto l’article 596, 4 avril 2011.pdf
Rapport du commissaire, Art. 582:596:598, 10 mai 2010.pdf
Rapport du conseil d’administration, articles 582:583:596:598, 21 juin 2010.pdf
Rapport du conseil d’administration, article 633, 10 mars 2010.pdf
Rapport du commissaire, article 596, 27 janvier 2009.pdf
Rapport du conseil d’administration, articles 583:596, 27 janvier 2009.pdf
Rapport du commissaire, article 596, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 603:596:589, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 583:596:589, 30 mai 2008 .pdf
Rapport du commissaire, article 596, 26 mai 2008.pdf
Rapport du conseil d’administration, articles 604, 27 mars 2008.pdf
Rapport du conseil d’administration, articles 603:596, 15 octobre 2007.pdf
Rapport du commissaire, article 596, 15 octobre 2007 .pdf
Rapport du conseil d’administration, articles 583:596:598, 25 mai 2007 .pdf
Rapport du commissaire, articles 596:598, 21 mai 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 18 avril 2007.pdf
Rapport du commissaire, article 596, 16 avril 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 8 november 2006.pdf
